Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

$1,444$1,3477%Neulasta® 897

223

1,1201,01510%NEUPOGEN®267

57

324332(2%)Enbrel®1,089

68

1,1571,0589%Aranesp®228

296

524536(2%)EPOGEN®502

0

502525(4%)Sensipar® / Mimpara®178

81

25923212%Vectibix®31

62

93903%Nplate®62

43

1058622%XGEVA®/ Prolia®

307

130

43729946%XGEVA®189

60

24917939%Prolia®118

70

18812057%Other 0

74

7427*Total product sales$3,561

$1,034

$4,595$4,2009%* Change in excess of 100%Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sales margin, excluding the impact of the Puerto Rico excise tax, was flat year-over-year.
  • R&D expenses increased 17 percent primarily in support of our later-stage clinical programs, including AMG 145.
  • Selling, General & Administrative (SG&A) expenses increased 3 percent driven primarily by higher ENBREL profit share expenses. ENBREL profit share expenses increased 15 percent to $425 million. 
  • $Millions, except percentagesOn an Adjusted BasisQ2 '13Q2 '12YOY ΔCost of Sales

    $714$6687%% of sales

    15.5%15.9%(0.4) pts.% of sales (Excluding PR excise tax)

    13.9%13.9%0 pts.Research & Development

    $944$80717%% of sales

    20.5%19.2%1.3 pts.Selling, General & Administrative

    $1,237$1,1993%% of sales

    26.9%28.5%(1.6) pts.TOTAL Operating Expenses$2,895$2,6748%pts: percentage points

  • Adjusted Tax Rate for the second quarter of 2013 reflects the favorable tax impacts of the federal R&D credit and changes in the jurisdictional mix of income and expe
    '/>"/>

  • SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
    2. Oncology remains most restrictive specialty for second year
    3. China Biologic Products to Report Second Quarter 2013 Financial Results
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
    7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
    8. Luminex Corporation Reports Second Quarter 2013 Results
    9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
    10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
    11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
    (Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
    (Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
    Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
    ... BERNARDINO, Calif., Jan. 25, 2011 Most people know ... know why they should take them or which vitamins ... are getting the vitamins they need, the Stater Bros. ... free 5-minute personal health survey.  The recommendations from this ...
    ... Jan. 25, 2011 Reportlinker.com announces that a ... catalogue: Emerging Regional Markets for ... The overall emerging markets for ... regions include Latin America, China, Eastern Europe, the ...
    Cached Medicine Technology:Stater Bros. Introduces Free Personal Vitamin Recommendation Program 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 3Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 4Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 5
    (Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
    (Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
    (Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
    (Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
    (Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
    Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
    ... By Amanda Gardner HealthDay Reporter , TUESDAY, ... during their younger years, especially women, are less likely ... types struggle with, researchers say. But regular exercise ... if it reached about 150 minutes of moderate to ...
    ... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
    ... UT Southwestern Medical Center have discovered sets of genes ... survival time and potential new treatments for patients with ... treatment vary widely and often depend on subtle biological ... pharmacology at UT Southwestern and co-lead author of the ...
    ... The latest weapon against inoperable liver cancer is so ... but according to interventional radiologists at the Indiana University ... therapeutic punch. The glass spheres contain a radioactive ... radiation for a very limited distance so that healthy ...
    ... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay News) ... key component of the new U.S. health-care reform law -- ... first successful challenge to the controversial legislation. ... Barack Obama and fellow Democrats against Republicans, will continue to ...
    ... , TUESDAY, Dec. 14 (HealthDay News) -- Scientists report ... associated with adrenal gland tumors by identifying 13 new ... adrenal gland, which is located above the kidney. These ... be cancerous -- cause the adrenal gland to produce ...
    Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
    ... three strongest enzymes available for maximum cleaning ... blood, tissue, mucous, and other organic matter ... in hard to reach places like box ... reduces the need for scrubbing and prolongs ...
    ... MPD is the highly concentrated ... instruments manually or with an ultrasonic ... to remove blood and organic material ... Use MPD to clean surgical instruments ...
    ... The Shandon Cytospin has ... over 35 years. More than ... simple, reliable instrument. It provides ... liquid matrix, especially hypocellular fluids ...
    The ISI Digi Grip has the strength needed for secure ,upper extremity traction....
    Medicine Products: